The latest price target for Bristol-Myers Squibb (NYSE:BMY) was reported by BMO Capital on September 23, 2024. The analyst firm set a price target for $48.00 expecting BMY to fall to within 12 months (a possible -6.34% downside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for Bristol-Myers Squibb (NYSE:BMY) was provided by BMO Capital, and Bristol-Myers Squibb maintained their market perform rating.

The last upgrade for Bristol-Myers Squibb Co happened on October 27, 2023 when HSBC raised their price target to $53. HSBC previously had a reduce for Bristol-Myers Squibb Co.

The last downgrade for Bristol-Myers Squibb Co happened on July 29, 2024 when Barclays changed their price target from $41 to $41 for Bristol-Myers Squibb Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bristol-Myers Squibb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bristol-Myers Squibb was filed on September 23, 2024 so you should expect the next rating to be made available sometime around September 23, 2025.

While ratings are subjective and will change, the latest Bristol-Myers Squibb (BMY) rating was a maintained with a price target of $48.00 to $48.00. The current price Bristol-Myers Squibb (BMY) is trading at is $51.25, which is out of the analyst’s predicted range.